Shares of Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) have earned a consensus rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and three have issued a strong buy recommendation on the company.
Separately, Chardan Capital upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, May 4th.
View Our Latest Research Report on GLX
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.gif){kind=logo}
